Evidence map›Paper›PMID 30271146›Full record

ArticleInternational journal of nanomedicine2018

Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.

Nian-Qiu Shi, Yan Li, Yong Zhang, Zheng-Qiang Li, Xian-Rong Qi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Nian-Qiu ShiSchool of Pharmacy, Jilin Medical University, Jilin, Jilin, 132013, China, shinianqiu2009@163.com.
Yan LiImmunology Department, Laboratory Medical College, Jilin Medical University, Jilin, Jilin, 132013, China.
Yong ZhangCollege of Life Science, Jilin University, Changchun, Jilin, 130012, China.
Zheng-Qiang LiKey Laboratory for Molecular Enzymology and Engineering, Ministry of Education, College of Life Science, Jilin University, Changchun, Jilin, 130012, China, lzq@jlu.edu.cn.
Xian-Rong QiDepartment of Pharmaceutics, School of Pharmaceutical Science, Peking University, Beijing, 100191, China.
Jilin Medical University · CNJilin University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcceleration and improvement of penetration across cell-membrane interfaces of active targeted nanotherapeutics into tumor cells would improve tumor-therapy efficacy by overcoming the issue of poor drug penetration. Cell-penetrating peptides, especially synthetic polyarginine, have shown promise in facilitating cargo delivery. However, it is unknown whether polyarginine can work to overcome the membrane interface in an inserted pattern for cyclic peptide ligand-mediated active targeting drug delivery. Here, we conducted a study to test the hypothesis that tandem-insert nona-arginine (tiR

methodsPolyarginine was coupled with the polyethylene glycol (PEG) chain and the cNGR moiety, yielding a cNGR-tiR

resultsThe accelerating active targeted liposome (Lip) nanocarrier (cNGR-tiR

conclusionThis active tumor-targeting nanocarrier incorporating a tandem-insert polyarginine (tiR

Indexed as

Drug Delivery SystemsNanomedicineAnimalsAntibiotics, AntineoplasticApoptosisCell-Penetrating PeptidesDoxorubicinFemaleFibrosarcomaHumansLigandsMiceMice, Inbred BALB CMice, NudePeptidesPeptides, CyclicAntibiotics, AntineoplasticCell-Penetrating Peptidescyclo(aspargyl-glycyl-arginyl)DoxorubicinLigandsliposomal doxorubicinPeptidesPeptides, CyclicpolyargininePolyethylene Glycolsaccelerating active targeting nanotherapeuticscNGRcyclic asparagine–glycine–argininemultifunctional nanomedicinespenetration and tumor therapytandem-insert nona-argininetiR9

Identifiers

PMID30271146
PMCPMC6154709
OpenAlexW2889605365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.